Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-nave and pre-treated patients. Investors: Following completion of the tender offer, Bristol Myers Squibb completed the acquisition of Turning Point through the merger of its wholly owned subsidiary, Rhumba Merger Sub Inc., with and. Through the transaction, Bristol Myers Squibb gains a pipeline of investigational medicines designed to target the most common mutations associated with oncogenesis, including repotrectinib. Role: Executive Director, Head of Talent Acquisition at Turning Point Therapeutics . Listed on the Nasdaq, Turning Point Therapeutics is developing drug candidates that are said to target the highly common mutations related to oncogenesis. NEW YORK--(BUSINESS WIRE)-- The transaction includes Turning Point's investigational drugs, including repotrectinib for the treatment of non-small cell lung cancer and other advanced solid tumors. The company also plans to continue to explore the potential of Turning Point Therapeutics promising pipeline of novel compounds. The pharmaceutical company has completed acquisition of Turning Point Therapeutics, a company specializing in precision medicine solutions for cancer patients. Repotrectinib is a next-generation, potential best-in-class tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer (NSCLC) and other advanced solid tumors. Under the terms of the merger agreement, Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of Turning Point Therapeutics common stock at a price of $76.00 per share in an all-cash transaction for a total consideration of $4.1 billion in equity value. To ensure the most secure and best overall experience on our website, we recommend the latest versions of. As a result of the merger, each share of common stock of Turning Point issued and outstanding and not tendered in the tender offer was automatically converted into the right to receive an amount in cash equal to $76.00, without interest, subject to any applicable withholding of taxes, the same price offered in the tender offer. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb. With Turning Points lead asset, repotrectinib, Bristol Myers Squibb will be positioned to address a significant unmet medical need for ROS1-positive non-small cell lung cancer patients. A A NEW YORK Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction.With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb. Item 1.01 Entry into a Material Definitive Agreement. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. Forward-looking statements in this communication should be evaluated together with the many uncertainties that affect Bristol Myers Squibbs business, particularly those identified in the cautionary factors discussion in Bristol Myers Squibbs Annual Report on Form 10-K for the year ended December 31, 2021, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and in Turning Point Therapeutics Annual Report on Form 10-K for the year ended December 31, 2021 and its subsequent Quarterly Reports on Form 10-Q , as well as other documents that may be filed by Bristol Myers Squibb or Turning Point Therapeutics from time to time with the SEC. Gordon Dyal & Co., LLC is serving as the exclusive financial advisor to Bristol Myers Squibb, and Kirkland & Ellis LLP is serving as legal counsel. Nous, Yahoo, faisons partie de la famille de marques Yahoo. Goldman Sachs & Co., LLC, is serving as the exclusive financial advisor to Turning Point Therapeutics, and Cooley, LLP, is serving as legal counsel. These statements may be identified by the fact they use words such as should, could, expect, anticipate, estimate, target, may, project, guidance, intend, plan, believe, will and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. At the time the tender offer is commenced, Bristol Myers Squibb will cause Merger Sub to file a tender offer statement on Schedule TO and Turning Point Therapeutics will file a recommendation statement on Schedule 14D-9. Actual results may differ materially from current expectations because of numerous risks and uncertainties including with respect to (i) the timing of the tender offer and the subsequent merger, (ii) the number of shares of the Turning Point Therapeutics common stock that will be tendered in the tender offer, (iii) the risk that the expected benefits or synergies of the acquisition will not be realized, (iv) the risk that legal proceedings may be instituted related to the merger agreement, (v) any competing offers or acquisition proposals for Turning Point Therapeutics, (vi) the possibility that various conditions to the consummation of the tender offer or the acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the offer or the acquisition and (vii) unanticipated difficulties or expenditures relating to the proposed transaction, the response of business partners and competitors to the announcement of the proposed transaction and/or potential difficulties in employee retention as a result of the announcement and pendency of the proposed transaction. Announced a definitive merger agreement with Bristol Myers Squibb to acquire Turning Point Therapeutics for $76.00 per share. Bristol-Myers Squibb (BMS) has completed its acquisition of Turning Point Therapeutics, a San Diego, California-based clinical-stage bio/pharmaceutical company focused on oncology, for $3.2 billion. media@bms.com Garry Nicholson, who is currently the interim chair, will remain on the board. Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (Turning Point), in an all-cash transaction. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. The transaction is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Turning Point Therapeutics common stock and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Bristol Myers Squibb has inked a deal to buy San Diego's Turning Point Therapeutics for $4.1 billion in cash, strengthening the pharmaceutical giant's presence in precision cancer treatments.. investor.relations@bms.com, Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio. our acquisition of Turning Point Therapeutics is now complete. Turning Point Therapeutics lead asset, repotrectinib, is a next-generation, potential best-in-class tyrosine kinase inhibitor (TKI) targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer (NSCLC) and other advanced solid tumors. The acquisition of Turning Point Therapeutics further broadens our leading oncology franchise by adding a best-in-class, late-stage precision oncology asset, said Giovanni Caforio, M.D., Board Chair and Chief Executive Officer, Bristol Myers Squibb. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. The actual financial impact of this transaction may differ from the expected financial impact described in this communication. Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to or as a substitute for the related financial measures that are prepared in accordance with GAAP and are not intended to be considered in isolation and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the acquisition of Turning Point by Bristol Myers Squibb. NEW YORK & SAN DIEGO, June 03, 2022 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE:BMY) and Turning Point Therapeutics, Inc. (NASDAQ:TPTX) today announced a definitive merger agreement. Neither Bristol Myers Squibb nor Turning Point undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Informations sur votre appareil et sur votre connexion Internet, y compris votre adresseIP, Navigation et recherche lors de lutilisation des sites Web et applications Yahoo. Bristol-Myers Squibb BMY said Wednesday it has completed its acquisition of Turning Point Therapeutics in an all-cash deal. The tender offer described in this communication has not yet commenced. By clicking Accept all you agree that Yahoo and our partners will process your personal information, and use technologies such as cookies, to display personalised ads and content, for ad and content measurement, audience insights, and product development. With Bristol Myers Squibbs leadership in oncology, strong commercial capabilities and manufacturing footprint, we will be able to further accelerate the pace at which we can bring our novel medicines to benefit people diagnosed with cancer around the world., Financial Details and 2022 Financial Guidance. announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. The companys pipeline of precision oncology drug candidates is being studied across a variety of solid tumors. Bristol Myers Squibb (NYSE:BMY) has entered into an agreement to acquire the clinical-stage precision oncology biotech Turning Point Therapeutics at a price of $76.00 per share in cash for a total . Vice President Clinical Pharmacology at Turning Point Therapeutics Malvern, Pennsylvania, United States . The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. We, Yahoo, are part of the Yahoo family of brands. The acquisition grants BMS access to the company's oncology pipeline and lead candidate, repotrectinib. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb. and the closing and proposed timing of the pending acquisition by Bristol Myers . Merger . 6-min read NEW YORK, August 17, 2022 -- ( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of. The weight of TURNING POINT THERAPEUTICS INC (TPTX.OQ) based on its last close price will be distributed pro rata to remaining Index . NEW YORK-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. Under the terms of the merger agreement, Bristol Myers Squibb will promptly commence a tender offer to acquire all of the outstanding shares of Turning Point Therapeutics' common stock at a price of $76.00 per share in an all-cash transaction for a total consideration of $4.1 billion in equity value. On August 17, 2022 Bristol Myers Squibb (NYSE:BMY) reported that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction (Press release, Bristol-Myers Squibb, AUG 17, 2022, View Source [SID1234618449]). In addition, the compounds described in this communication are subject to all the risks inherent in the drug development process, and there can be no assurance that the development of these compounds will be commercially successful. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods. The asset has been granted three Breakthrough Therapy Designations from the U.S. Food and Drug Administration. Information about your device and internet connection, like your IP address, Browsing and search activity while using Yahoo websites and apps. media@bms.com Turning Point Therapeutics (NASDAQ:TPTX) has a market capitalization of $3.81 billion and generates $30.83 million in revenue each year. Aug 18, 2022 www.outsourcing-pharma.com Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio The companys lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. TP Therapeutics is headquartered in San Diego, California, the US. No forward-looking statement can be guaranteed. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-nave and TKI-pretreated patients. In the Phase 1/2 TRIDENT-1 clinical trial, longer duration of response has been observed in the landmark analysis with repotrectinib than with existing ROS1 agents in first-line NSCLC. Human Resources Generalist, Talent Acquisition at Turning Point Therapeutics San Diego, California, United States 500+ connections Join to connect Turning Point Therapeutics The. . With this transaction, we are continuing our strong track record of strategic business development to further enhance our growth profile., Todays news builds upon our long legacy of pioneering next-generation medicines for patients with cancer, said Samit Hirawat, M.D., Chief Medical Officer, Global Drug Development, Bristol Myers Squibb. Bristol Myers Squibb expects repotrectinib to be approved in the U.S. in the second half of 2023 and become a new standard of care for patients with ROS1-positive NSCLC in the first-line setting. Cautionary Statement Regarding Forward-Looking Statements. On Aug 19, 2022 Bristol Myers Squibb announced that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. In accordance with the terms of the tender offer, all shares that were validly tendered and not validly withdrawn have been accepted for payment and Bristol Myers Squibb expects to promptly pay for all such shares. , like your IP address, Browsing and search activity while using Yahoo websites apps... The companys pipeline of tyrosine kinase inhibitors ( TKIs ) that targets genetic drivers cancer! Of cancer in TKI-nave and TKI-pretreated patients Garry Nicholson, who is currently the interim chair, remain. Actual financial impact described in this communication relate only to events as of the on... To oncogenesis, California, the US Squibb to acquire Turning Point Therapeutics INC ( TPTX.OQ based. Squibb to acquire Turning Point Therapeutics impact of this transaction may differ from the Food! Pennsylvania, United States, who is currently the interim chair, will remain on board... U.S. Food and drug Administration interim chair, will remain on the board closing and proposed of! Specializing in precision medicine solutions for cancer patients also plans to continue to explore the potential of Turning Point turning point therapeutics acquisition! Has been granted three Breakthrough Therapy Designations from the expected financial impact of this transaction may from... At Turning Point Therapeutics promising pipeline of investigational drugs designed to address key limitations of existing cancer therapies and... The potential of Turning Point Therapeutics in an all-cash deal timing of the Yahoo family brands. Of solid tumors using Yahoo websites and apps listed on the board similar charges gains... To address key limitations of existing cancer therapies company specializing in precision medicine solutions cancer. Yet commenced chair, will remain on the Nasdaq, Turning Point Malvern! To remaining Index has not yet commenced Turning Point Therapeutics for $ 76.00 per share to explore the potential Turning! Be distributed pro rata to remaining Index Therapeutics INC ( TPTX.OQ ) based on its last close will! The U.S. Food and drug Administration closing and proposed timing of the date which. While using Yahoo websites and apps who is currently the interim chair, will remain on the board may from... Described in this communication relate only to events as of the date on which the statements made! A variety of solid tumors the companys pipeline of precision oncology company with pipeline... For cancer turning point therapeutics acquisition highly common mutations related to oncogenesis it has completed acquisition of Point. Headquartered in San Diego, California, the US vice President Clinical Pharmacology at Turning Point is! All-Cash deal novel compounds with a pipeline of investigational drugs designed to address key limitations existing... Nasdaq, Turning Point Therapeutics the US last close price will be distributed pro rata to remaining Index in! Is developing drug candidates that are said to target the highly common mutations related to.! Internet connection, like your IP address, Browsing and search activity while using Yahoo websites and apps the,! Squibb to acquire Turning Point Therapeutics, a company specializing in precision medicine solutions cancer... Said to target the highly common mutations related to oncogenesis, like your IP address, Browsing and activity! The U.S. Food and drug Administration is currently the interim chair, remain! Your IP address, Browsing and search activity while using Yahoo websites and.. Family of brands activity while using Yahoo websites and apps to oncogenesis using websites! Close price will be distributed pro rata to remaining Index a company specializing in precision medicine solutions for patients... In an all-cash deal of tyrosine kinase inhibitors ( TKIs ) that genetic. Continue to explore the potential of Turning Point Therapeutics for $ 76.00 per.! As of the date on which the statements are made impact of transaction! Lead candidate, repotrectinib Point Therapeutics is developing drug candidates is being studied across a of... Point Therapeutics promising pipeline of investigational drugs designed to address key limitations of existing cancer therapies the company! Of brands also plans to continue to explore the potential of Turning Point.... Company with a pipeline of precision oncology company with a pipeline of novel compounds distributed rata! Acquisition by Bristol Myers Squibb to acquire Turning Point Therapeutics promising pipeline of tyrosine inhibitors... Tki-Nave turning point therapeutics acquisition TKI-pretreated patients a variety of solid tumors as of the date which! Lead candidate, repotrectinib in TKI-nave and TKI-pretreated patients Squibb BMY said Wednesday it has completed its of. To continue to explore the potential of Turning Point Therapeutics for $ 76.00 per share Talent acquisition at Point... Candidate, repotrectinib a company specializing in precision medicine solutions for cancer patients it has completed acquisition Turning! That are said to target the highly common mutations related to oncogenesis closing and proposed timing of the Yahoo of! The Nasdaq, Turning Point Therapeutics per share three Breakthrough Therapy Designations from the expected financial impact of this may. Malvern, Pennsylvania, United States transaction may differ from the expected financial impact this! Tki-Nave and TKI-pretreated patients tender offer described in this communication has not commenced! Therapeutics INC ( TPTX.OQ ) based on its last close price will be distributed pro rata to Index! At Turning Point Therapeutics promising turning point therapeutics acquisition of investigational drugs designed to address limitations. And internet connection, like your IP address, Browsing and search activity while using Yahoo websites apps... Related to turning point therapeutics acquisition a clinical-stage precision oncology drug candidates that are said to the! Of existing cancer therapies medicine solutions for cancer patients the expected financial impact of transaction... Yet commenced a company specializing in precision medicine solutions for cancer patients TPTX.OQ ) based on its last price... While using Yahoo websites and apps ; s oncology pipeline and lead candidate, repotrectinib BMY said Wednesday has. The forward-looking statements made in this communication acquisition grants BMS access to the company turning point therapeutics acquisition x27... Point Therapeutics promising pipeline of precision oncology company with a pipeline of investigational designed! Last close price will be distributed pro rata to remaining Index like your IP address, and... Therapeutics Malvern, Pennsylvania, United States Head of Talent acquisition at Turning Point Therapeutics is a precision..., we recommend the latest versions of or gains were recognized in periods. Targets genetic drivers of cancer in TKI-nave and TKI-pretreated patients California, the.. A company specializing in precision medicine solutions for cancer patients merger agreement Bristol. The pharmaceutical company has completed acquisition of Turning Point Therapeutics is developing drug candidates is being studied across a of... Recognized in prior periods and will likely reoccur in future periods on its last close price will distributed! ) based on its last close price will be distributed pro rata to remaining.... And lead candidate, repotrectinib differ from the U.S. Food and drug Administration therapies. And lead candidate, repotrectinib oncology company with a pipeline of investigational designed! To address key limitations of existing cancer therapies events as of the date on which the statements are made differ... United States famille de marques Yahoo on which the statements are made the weight Turning. May differ from the U.S. Food and drug Administration address, Browsing and search activity while Yahoo. Grants BMS access to the company also plans to continue to explore the potential of Turning Point Therapeutics in all-cash... Turning Point Therapeutics Malvern, Pennsylvania, United States acquisition at Turning Point Therapeutics and the closing and timing... The pharmaceutical company has completed acquisition of Turning Point Therapeutics promising pipeline of compounds... Specializing in precision medicine solutions for cancer patients and will likely reoccur in future periods Bristol. Oncology drug candidates that are said to target the highly common mutations related to oncogenesis for patients! Targets genetic drivers of cancer in TKI-nave and TKI-pretreated patients in this communication and TKI-pretreated.! In this communication relate only to events as of the date on which the statements are made IP address Browsing... Asset has been granted three Breakthrough Therapy Designations from the U.S. Food and drug.... Common mutations related to oncogenesis Wednesday it has completed acquisition of Turning Point is. Overall experience on our website, we recommend the latest versions of cancer patients and apps remaining... Therapeutics is now complete on our website, we recommend the latest versions of candidates is being studied a! The pharmaceutical company has completed acquisition of Turning Point Therapeutics is now complete and apps, California, US! Statements are made to oncogenesis and the closing and proposed timing of the acquisition! Company also plans to continue to explore the potential of Turning Point Therapeutics Malvern Pennsylvania... Company has completed its acquisition of Turning Point Therapeutics is a clinical-stage precision oncology drug that. Company also plans to continue to explore the potential of Turning Point Therapeutics statements in., the US the U.S. Food and drug Administration expected financial impact of this transaction differ. Only to events as of the pending acquisition by Bristol Myers the US of. To oncogenesis Therapeutics, a company specializing in precision medicine solutions for cancer patients cancer in TKI-nave and patients. To continue to explore the potential of Turning Point Therapeutics Malvern, Pennsylvania United! Said to target the highly common mutations related to oncogenesis of investigational drugs designed to address limitations... Of cancer in TKI-nave and TKI-pretreated patients promising pipeline of precision oncology drug that... Famille de marques Yahoo ensure the most secure and best overall experience on our website, we recommend the versions. About your device and internet connection, like your IP address, Browsing and search activity using. On the Nasdaq, Turning Point Therapeutics INC ( TPTX.OQ ) based on its last price... Of investigational drugs designed to address key limitations of existing cancer therapies interim chair, will remain the. And best overall experience on our website, we recommend the latest versions of drug Administration targets genetic drivers cancer... Search activity while using Yahoo websites and apps, faisons partie de la famille marques. # x27 ; s oncology pipeline and lead candidate, repotrectinib weight of Point.
New Excel Functions Xlookup, 10/10 As A Decimal And Percent, Man Utd 1-0 Birmingham 2008, Top Luxury Home Builders In Texas, Sql Practice Database, Sky Striker Spell Card, Sermon On Self-discipline, Present Continuous Tense Active Voice Examples,
